SIM0270 is named as a drug or biological intervention in 3 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is Jiangsu Simcere Pharmaceutical Co., Ltd.. Registered phases: Phase 1 and Phase 3. Conditions studied include Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Healthy Adult Participants.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07357610 | An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants (ClinicalTrials.gov ↗) Healthy Adult Participants |
Phase 1 | Recruiting |
| NCT06680921 | A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) Locally Advanced or Metastatic Breast Cancer |
Phase 3 | Active, closed |
| NCT05293964 | Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Locally Advanced or Metastatic Breast Cancer | 1 |
| Breast Cancer | 1 |
| Healthy Adult Participants | 1 |
| Lead sponsor | Trials |
|---|---|
| Jiangsu Simcere Pharmaceutical Co., Ltd. | 3 |
| Register | SIM0270 trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SIM0270 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SIM0270 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.